TY - JOUR
T1 - Weak microbial metabolites
T2 - A treasure trove for using biomimicry to discover and optimize drugs
AU - Dvorak, Zdenek
AU - Klapholz, Max
AU - Burris, Thomas P.
AU - Willing, Benjamin P.
AU - Gioiello, Antimo
AU - Pellicciari, Roberto
AU - Galli, Francesco
AU - March, John
AU - O'Keefe, Stephen J.
AU - Balfour Sartor, R.
AU - Kim, Chang H.
AU - Levy, Maayan
AU - Mani, Sridhar
N1 - Funding Information:
This study was supported in part by The Peer Reviewed Medical Research Program – Investigator Initiated Research Award [Award No. W81XWH-17-1-0479], by National Institutes of Health (NIH) National Institute of Environmental Health Sciences [Grant R01 ES030197] and National Cancer Institute [Grant R01 CA222469], and The Czech Science Foundation [Grant 20-00449S].
Publisher Copyright:
Copyright © 2020 by The American Society for Pharmacology and Experimental Therapeutics
PY - 2020/10
Y1 - 2020/10
N2 - For decades, traditional drug discovery has used natural product and synthetic chemistry approaches to generate libraries of compounds, with some ending as promising drug candidates. A complementary approach has been to adopt the concept of biomimicry of natural products and metabolites so as to improve multiple drug-like features of the parent molecule. In this effort, promiscuous and weak interactions between ligands and receptors are often ignored in a drug discovery process. In this Emerging Concepts article, we highlight microbial metabolite mimicry, whereby parent metabolites have weak interactions with their receptors that then have led to discrete examples of more potent and effective drug-like molecules. We show specific examples of parent-metabolite mimics with potent effects in vitro and in vivo. Furthermore, we show examples of emerging microbial ligand-receptor interactions and provide a context in which these ligands could be improved as potential drugs. A balanced conceptual advance is provided in which we also acknowledge potential pitfalls-hyperstimulation of finely balanced receptor-ligand interactions could also be detrimental. However, with balance, we provide examples of where this emerging concept needs to be tested.
AB - For decades, traditional drug discovery has used natural product and synthetic chemistry approaches to generate libraries of compounds, with some ending as promising drug candidates. A complementary approach has been to adopt the concept of biomimicry of natural products and metabolites so as to improve multiple drug-like features of the parent molecule. In this effort, promiscuous and weak interactions between ligands and receptors are often ignored in a drug discovery process. In this Emerging Concepts article, we highlight microbial metabolite mimicry, whereby parent metabolites have weak interactions with their receptors that then have led to discrete examples of more potent and effective drug-like molecules. We show specific examples of parent-metabolite mimics with potent effects in vitro and in vivo. Furthermore, we show examples of emerging microbial ligand-receptor interactions and provide a context in which these ligands could be improved as potential drugs. A balanced conceptual advance is provided in which we also acknowledge potential pitfalls-hyperstimulation of finely balanced receptor-ligand interactions could also be detrimental. However, with balance, we provide examples of where this emerging concept needs to be tested.
UR - http://www.scopus.com/inward/record.url?scp=85090869388&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85090869388&partnerID=8YFLogxK
U2 - 10.1124/MOLPHARM.120.000035
DO - 10.1124/MOLPHARM.120.000035
M3 - Article
C2 - 32764096
AN - SCOPUS:85090869388
SN - 0026-895X
VL - 98
SP - 343
EP - 349
JO - Molecular Pharmacology
JF - Molecular Pharmacology
IS - 4
ER -